Evaluating the Treatment of Chemotherapy-Induced Nausea and Vomiting

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

The editors in chief of The American Journal of Managed Care® discuss the key managed care research and news from 2024 and look forward to the journal’s upcoming 30th anniversary.

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for patients, especially those who experience loss of response.

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.

Latine individuals in the US face higher morbidity and mortality in skin cancer outcomes despite lower lifetime risk.

For diverse patient populations who are historically marginalized within health care, student-run clinics may offer a potentially cost-effective access point to dermatological care.